获取途径

作者

Li, Ran Zhang, Ye Liu, Qian Gao, Aiqin Dang, Qi

作者单位

Department of Oncology, Phase I Clinical Trial Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China. a Shandong Second Medical University, Weifang, China Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan, China

刊名

Medicine

年份

2024

卷号

Vol.103 No.52

页码

e38881

关键词

midline carcinoma nuclear protein of testis carcinoma NUT carcinoma pulmonary targeted therapy

摘要

Rationale: Nuclear protein in testis carcinoma is a rare, aggressive, poorly differentiated squamous cell carcinoma. By reviewing the entire treatment process of the patient, we aim to explore the treatment experience of NC. Patient concerns: We report the case of a 27-year-old female patient with NC whose initial symptoms were occasional cough and chest tightness with abdominal distension for more than half a month without any other specific discomfort. Diagnoses: Computed tomography showed ri...更多

Rationale: Nuclear protein in testis carcinoma is a rare, aggressive, poorly differentiated squamous cell carcinoma. By reviewing the entire treatment process of the patient, we aim to explore the treatment experience of NC. Patient concerns: We report the case of a 27-year-old female patient with NC whose initial symptoms were occasional cough and chest tightness with abdominal distension for more than half a month without any other specific discomfort. Diagnoses: Computed tomography showed right lung hilar and right middle and lower lobe mass, malignant, right hilar and mediastinal lymph node metastasis, and bilateral cystic solid masses in the adnexal region, malignant possibility. Pathological diagnosis showed nuclear protein in the testis . Interventions: After the failure of first-line chemotherapy with immunocombination, second-line chemotherapy was switched to bevacizumab, which resulted in a progression-free survival of 6 months. Outcomes: The disease then reprogressed, and she died on November 7, 2022. Lessons: The patient achieved survival of nearly 1 year on multiple courses of therapy, well beyond the currently reported median survival. The patient achieved a 6-month progression-free survival, suggesting that combination therapy with antivascular endothelial growth factor class-targeted agents is a potential approach.收起

文献类型

期刊